Topotecan enhances immune clearance of gliomas.
Despite aggressive surgery, radiation therapy, and chemotherapy, glioblastoma multiforme (GBM) is refractory to therapy, recurs quickly, and results in a median survival time of only 14 months. The modulation of the apoptotic receptor Fas with cytotoxic agents could potentiate the response to therapy. However, Fas ligand (FasL) is not expressed in the brain and therefore this Fas-inducing cell death mechanism cannot be utilized. Vaccination of patients with gliomas has shown promising responses. In animal studies, brain tumors of vaccinated mice were infiltrated with activated T cells. Since activated immune cells express FasL, we hypothesized that combination of immunotherapy with chemotherapy can activate Fas signaling, which could be responsible for a synergistic or additive effect of the combination. When we treated the human glioma cell line U-87 and GBM tumor cells isolated from patients with TPT, Fas was up regulated. Subsequent administration of soluble Fas ligand (sFasL) to treated cells significantly increased their cell death indicating that these Fas receptors were functional. Similar effect was observed when CD3(+) T cells were used as a source of the FasL, indicating that the up regulated Fas expression on glioma cells increases their susceptibility to cytotoxic T cell killing. This additive effect was not observed when glioma cells were pre-treated with temozolomide, which was unable to increase Fas expression in tumor. Inhibition of FasL activity with the antagonistic antibody Nok-1 mitigated these effects confirming that these responses were specifically mediated by the Fas-FasL interaction. Furthermore, the CD3(+) T cells co-cultured with topotecan treated U-87 and autologous GBM tumor cells showed a significant increase in expression in IFN-gamma, a key cytokine produced by activated T cells, and accordingly enhanced tumor cytotoxicity. Based on our data we conclude that drugs, such as topotecan, which cause up regulation of Fas on glioma cells can be potentially exploited with immunotherapy to enhance immune clearance of tumors via Fas signaling.
Wei
Jun
J
Department of Neurosurgery, Unit 442, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
DeAngulo
Guillermo
G
Sun
Wei
W
Hussain
Sakina F
SF
Vasquez
Hernan
H
Jordan
Justin
J
Weinberg
Jeffery
J
Wolff
Johannes
J
Koshkina
Nadya
N
Heimberger
Amy B
AB
D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects; D001932:Brain Neoplasms / Q000276:immunology* / Q000628:therapy; D017252:CD3 Complex / Q000378:metabolism; D045744:Cell Line, Tumor; D053222:Fas Ligand Protein / Q000378:metabolism; D005434:Flow Cytometry; D005909:Glioblastoma / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007167:Immunotherapy; D007371:Interferon-gamma / Q000378:metabolism; D015398:Signal Transduction; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology*; D019772:Topotecan / Q000276:immunology / Q000494:pharmacology*; D015854:Up-Regulation / Q000187:drug effects; D019014:fas Receptor / Q000378:metabolism
D017252:CD3 Complex; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D019014:fas Receptor; D019772:Topotecan; D007371:Interferon-gamma